Companies Rezolute, Inc.
Rezolute (RZLT): executive pay, fiscal 2026
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Rezolute, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,192,700FY2024
- $2,851,109FY2025
- $5,711,410FY2026
CEO total pay was $5,711,410 in fiscal 2026, up from $2,851,109 in fiscal 2025.
FY2026: salary $655,000 · bonus $450,912 · stock awards $3,220,720 · option awards $1,358,972
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nevan Charles Elam | $655,000 | $450,912 | $3,220,720 | $1,358,972 | $0 | $0 | $25,806 | $5,711,410 |
| Chief Executive Officer | ||||||||
| Sunil Karnawat | 415,625 | 237,301 | 488,870 | 1,456,235 | 0 | 0 | 25,878 | 2,623,909 |
| Chief Commercial Officer | ||||||||
| Brian Roberts | 512,164 | 226,826 | 1,249,680 | 526,054 | 0 | 0 | 50,233 | 2,564,957 |
| Chief Medical Officer | ||||||||
| Daron Evans | 480,000 | 242,666 | 1,087,120 | 460,297 | 0 | 0 | 15,383 | 2,285,466 |
| Chief Financial and Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Nevan Charles Elam | $5,711,410 | $2,851,109 | $1,192,700 | ↑ +2,860,301 |
| Sunil Karnawat | 2,623,909 | — | — | — |
| Brian Roberts | 2,564,957 | 1,434,728 | 817,959 | ↑ +1,130,229 |
| Daron Evans | 2,285,466 | 1,715,661 | 384,065 | ↑ +569,805 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation program is designed to attract and retain qualified executive officers by providing competitive base salaries and annual cash bonuses based on the achievement of performance criteria set forth by the Board of Directors. Long-term incentives are provided through equity awards, including stock options and restricted stock units, to align executive interests with stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2026
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brian Roberts | Option | 10,000 | 4.39 | — |
| Daron Evans | Option | 10,000 | 4.39 | — |
| Brian Roberts | Option | 25,000 | 4.61 | — |
| Daron Evans | Option | 25,000 | 4.61 | — |
| Brian Roberts | Option | 25,278 | 1.02 | — |
| Brian Roberts | RSU | 26,000 | — | 135,200 |
| Daron Evans | RSU | 26,000 | — | 135,200 |
| Nevan Charles Elam | Option | 26,667 | 4.39 | — |
| Daron Evans | Option | 50,750 | 10.16 | — |
| Brian Roberts | RSU | 51,333 | — | 266,932 |
| Daron Evans | RSU | 51,333 | — | 266,932 |
| Daron Evans | Option | 56,250 | 4.79 | — |
| Brian Roberts | Option | 58,000 | 10.16 | — |
| Nevan Charles Elam | Option | 66,112 | 1.02 | — |
| Nevan Charles Elam | Option | 66,667 | 4.61 | — |
| Nevan Charles Elam | RSU | 68,000 | — | 353,600 |
| Daron Evans | RSU | 107,000 | — | 556,400 |
| Daron Evans | Option | 108,855 | 1.02 | — |
| Brian Roberts | RSU | 123,000 | — | 639,600 |
| Nevan Charles Elam | RSU | 136,000 | — | 707,200 |
| Nevan Charles Elam | Option | 149,834 | 10.16 | — |
| Nevan Charles Elam | RSU | 317,000 | — | 1,648,400 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gil LabrucherieIndependent · Audit (Chair) · Nominating and Governance | $72,250 | $213,360 | $87,676 | — | — | $373,286 |
| Wladimir Hogenhuis, M.DIndependent · Audit · Compensation (Chair) · Partial-year service | 68,500 | 213,360 | 87,676 | — | — | 369,536 |
| Nerissa Kreher, M.DIndependent · Compensation · Nominating and Governance (Chair) · Partial-year service | 65,750 | 213,360 | 87,676 | — | — | 366,786 |
| Philippe FauchetIndependent · Audit · Nominating and Governance | 62,250 | 213,360 | 87,676 | — | — | 363,286 |
| Erik HarrisIndependent · Compensation | 52,250 | 213,360 | 87,676 | — | — | 353,286 |
| Young-Jin KimNot independent | 45,000 | 213,360 | 87,676 | — | — | 346,036 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 13,500 / 13,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $366,000 |
| Equity awards (grant-date value) | $1,280,160 |
| All other compensation | $0 |
| Total cost of the board | $1,646,160 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Rezolute as a peer
Companies that benchmark against RZLT
5 companies name RZLT as a compensation peer
- Altimmune, Inc.ALTFY2025
- Cartesian Therapeutics, Inc.RNACFY2025
- NEKTAR THERAPEUTICSNKTRFY2025
- ORAMED PHARMACEUTICALS INC.ORMPFY2024
- Trevi Therapeutics, Inc.TRVIFY2025
Each company listed discloses RZLT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RZLT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rezolute, Inc. | 2026 | Nevan Charles Elam | $655,000 | $3,220,720 | $1,358,972 | $0 | $5,711,410 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2026 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Daron Evans | CFO | 2026-10-21 | A | 4,000 | $0 | $0 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2026-10-21 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2026-10-21 | D | 16,000 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (17 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nevan Charles Elam. DEF 14A, filed 2026-10-21. Section “Executive Compensation”. As printed: 5,711,410. View filing ↗
- Section 01, Sunil Karnawat. DEF 14A, filed 2026-10-21. Section “Executive Compensation”. As printed: 2,623,909. View filing ↗
- Section 01, Brian Roberts. DEF 14A, filed 2026-10-21. Section “Executive Compensation”. As printed: 2,564,957. View filing ↗
- Section 01, Daron Evans. DEF 14A, filed 2026-10-21. Section “Executive Compensation”. As printed: 2,285,466. View filing ↗
- Section 07, pay ratio. 10-K, filed 2025-09-17. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Gil Labrucherie. DEF 14A, filed 2026-10-21. Section “Director Compensation”. As printed: 373,286. View filing ↗
- Section 08, Wladimir Hogenhuis, M.D. DEF 14A, filed 2026-10-21. Section “Director Compensation”. As printed: 369,536. View filing ↗
- Section 08, Nerissa Kreher, M.D. DEF 14A, filed 2026-10-21. Section “Director Compensation”. As printed: 366,786. View filing ↗
- Section 08, Philippe Fauchet. DEF 14A, filed 2026-10-21. Section “Director Compensation”. As printed: 363,286. View filing ↗
- Section 08, Erik Harris. DEF 14A, filed 2026-10-21. Section “Director Compensation”. As printed: 353,286. View filing ↗
- Section 08, Young-Jin Kim. DEF 14A, filed 2026-10-21. Section “Director Compensation”. As printed: 346,036. View filing ↗
- Section 02, Daron Evans 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daron Evans 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daron Evans 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 366,000 + equity 1,280,160 + all other 0 = 1,646,160, summed across the director compensation table rows.
- Rezolute, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-10-21. CEO total compensation as printed in Rezolute, Inc.'s own proxy. As printed: 5,711,410. View filing ↗